特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
962421

リキッドバイオプシーの世界市場 (2020-2030年):製品タイプ・適応症・技術・バイオマーカー・臨床用途・検体タイプ・用途・ワークフロー・地域別

Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, Indication Type, Technology, Biomarker, Clinical Applications, Sample Type, Usage, Workflow, Geographical & Competitive Landscape-Analysis & Forecast, 2020 - 2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 302 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.41円
リキッドバイオプシーの世界市場 (2020-2030年):製品タイプ・適応症・技術・バイオマーカー・臨床用途・検体タイプ・用途・ワークフロー・地域別
出版日: 2020年09月25日
発行: BIS Research Inc.
ページ情報: 英文 302 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリキッドバイオプシーの市場規模は2030年には129億米ドルの規模に成長すると予測されています。癌の有病率の増加、市場における無機成長戦略の導入拡大、NCIによる資金提供の増加などの要因が同市場の成長を推進しています。

当レポートでは、世界のリキッドバイオプシーの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制の枠組み、償還シナリオ、資金調達シナリオ、技術・特許の動向、市場規模の推移・予測、製品・技術・ワークフロー・用途・検体・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 市場範囲

第3章 調査手法

第4章 市場概要

  • 市場規模・将来の成長の可能性
  • これまでの動向
  • 組織生検・リキッドバイオプシーの比較分析
  • リキッドバイオプシー技術の比較分析

第5章 産業考察

  • 承認シナリオ
  • 規制の枠組み:地域別
  • 償還シナリオ
  • 特許分析
  • 資金調達シナリオ
  • サプライチェーン分析
  • 製品マッピング分析
  • 医師の認識
  • 投資家の認識
  • 政府イニシアチブ
  • COVID-19の影響

第6章 市場力学

  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第7章 競合考察

  • 主な戦略・展開
  • 市場シェア分析
  • 成長シェア分析

第8章 市場分析・予測:製品別

  • テスト・サービス
  • キット・消耗品
  • 機器

第9章 市場分析・予測:技術別

  • 次世代シーケンシング
  • ポリメラーゼ連鎖反応
    • デジタルPCR
    • マルチプレックスPCR
    • リアルタイムPCR
    • その他
    • 蛍光insituハイブリダイゼーション
  • その他

第10章 市場分析・予測:ワークフロー別

  • サンプル準備
  • ライブラリ準備
  • シーケンス
  • データ分析・管理

第11章 市場分析・予測:用途別

  • 臨床
  • 研究

第12章 市場分析・予測:検体別

  • 血液
  • 非血液
    • 尿
    • 唾液
    • 脳脊髄液

第13章 市場分析・予測:循環バイオマーカー別

  • 循環腫瘍細胞(CTC)
  • 無細胞DNA(cfDNA)
  • 無細胞RNAの循環
  • エクソソーム・細胞外小胞・その他
  • その他

第14章 市場分析・予測:適応症別

  • 肺癌
  • 乳癌
  • 前立腺癌
  • 結腸直腸癌
  • 黒色腫
  • 他の癌
  • 癌以外の疾患

第15章 市場分析・予測:臨床用途別

  • 治療モニタリング
  • 予後・再発モニタリング
  • 治療法の選択
  • 診断・スクリーニング

第16章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
  • インド
    • オーストラリア
    • 韓国
    • シンガポール
  • その他
  • 中南米・中東
    • ブラジル
    • メキシコ
    • サウジアラビア
    • その他
  • その他の地域

第17章 企業プロファイル

  • Abcodia Ltd.
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cynvenio Biosystems, Inc.
  • Chronix Biomedical
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • GUARDANT HEALTH, INC
  • Illumina, Inc.
  • Menarini Silicon Biosystems, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics, Inc.
  • Qiagen N.V.
  • Resolution Bioscience, Inc.
  • Thermo Fisher Scientific
図表

List of Tables

  • Table 1: Most Common Cancers
  • Table 2: Existing Patients Issues with Standard Tissue Biopsies and Surgical Procedures
  • Table 4.1: Global Liquid Biopsy Market, by Region, ($Million), 2019-2030
  • Table 4.2: Comparative Analysis of Liquid Biopsy vs. Tissue Biopsy
  • Table 4.3: Comparative Analysis of Liquid Biopsy Technologies
  • Table 5.1: Approved Liquid Biopsy Test Kits from Major Players
  • Table 5.2: List of Other Non-EGFR Liquid Biopsies Kits
  • Table 5.3: List of Major Players Liquid Biopsies
  • Table 5.4: Elements for the Liquid Biopsy Regulatory Submission
  • Table 5.5: Reimbursement Scenario for Key Players Offerings in Global Liquid Biopsy Market
  • Table 5.6: Reimbursement Landscaping for Liquid Biopsies (FY2015-FY2019)
  • Table 5.7: Global Liquid Biopsy Market (Key Players Patent Portfolio)
  • Table 5.8: Investment Heat Map
  • Table 5.9: Investors Heat Map
  • Table 5.10: Liquid Biopsy Product Mapping Analysis (by Technology Type)
  • Table 5.11: Liquid Biopsy Product Mapping Analysis (by Sample Type)
  • Table 5.12: Liquid Biopsy Product Mapping Analysis by Biomarker
  • Table 5.13: Liquid Biopsy Product Mapping Analysis by Application
  • Table 5.14: Government Initiatives for Liquid Biopsies
  • Table 6.1: Pricing List of Key Players Liquid Biopsies
  • Table 13.1: Comparison between the applications of ctDNA, CTCs, and exosomes
  • Table 16.1: Type-Specific Prevalence of Cancers in the U.S
  • Table 16.2: Type-specific Prevalence of Cancers in Canada
  • Table 16.3: Type-Specific Prevalence of Cancers in Germany
  • Table 16.4: Type-Specific Prevalence of Cancers in France
  • Table 16.5: Type-Specific Prevalence of Cancers in the U.K
  • Table 16.6: Type-specific Prevalence of Cancers in Italy
  • Table 16.7: Type-Specific Prevalence of Cancers in Spain
  • Table 16.8: Type-Specific Prevalence of Cancers in China
  • Table 16.9: Type-Specific Prevalence of Cancers in Japan
  • Table 16.10: Type-Specific Prevalence of Cancers in India
  • Table 16.11: Type-Specific Prevalence of Cancers in Australia
  • Table 16.12: Type-Specific Prevalence of Cancers in South Korea
  • Table 16.13: Type-Specific Prevalence of Cancers in Singapore
  • Table 16.14: Type-Specific Prevalence of Cancers in Brazil
  • Table 16.15: Type-specific Prevalence of Cancers in Mexico
  • Table 16.16: Type-Specific Prevalence of Cancers in Saudi Arabia

List of Figures

  • Figure 1: Type of Cancer Diagnostics
  • Figure 2: Considerations for Liquid Biopsy
  • Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global Liquid Biopsy Market
  • Figure 4: Global Liquid Biopsy Market (by Technology), $Million, 2020 and 2030
  • Figure 5: Global Liquid Biopsy Market (by Workflow), $Million, 2020 and 2030
  • Figure 6: Global Liquid Biopsy Market (by Usage), $Million, 2020 and 2030
  • Figure 7: Global Liquid Biopsy Market (by Type of Sample), $Million, 2020 and 2030
  • Figure 8: Global Liquid Biopsy Market (by Circulating Biomarkers), $Million, 2020 and 2030
  • Figure 9: Global Liquid Biopsy Market (by Products), $Million, 2020 and 2030
  • Figure 10: Global Liquid Biopsy Market (by Indication), $Million, 2020 and 2030
  • Figure 11: Global Liquid Biopsy Market (by Clinical Application), $Million, 2020 and 2030
  • Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2019
  • Figure 2.1: Global Liquid Biopsy Market Segmentation
  • Figure 3.1: Global Liquid Biopsy Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Liquid Biopsy Market, 2019-2030 ($Million)
  • Figure 4.2: Historical Evolution of Liquid Biopsy Testing
  • Figure 5.1: Key Findings from Liquid Biopsy Reimbursement Study
  • Figure 5.2: Liquid Biopsy Market, Percent Split of Filed Patients (FY2014-FY2018)
  • Figure 5.3: Liquid Biopsy Patent Analysis (FY2014-FY2018)
  • Figure 5.4: Patent Expiration Analysis
  • Figure 5.5: Key Players Financing Stratification
  • Figure 5.6: Financing Analysis (FY2017-FY2019), US$ Million
  • Figure 5.7: Liquid Biopsies Key Players Financing Analysis
  • Figure 5.8: Liquid Biopsy Supply Chain Analysis
  • Figure 5.9: Physicians Perceptions for Liquid Biopsies
  • Figure 5.10: Investors Perception
  • Figure 5.11: Recent Government Initiatives to Debunk the Negative Impact of COVID-19 on Liquid Biopsy Industry
  • Figure 5.12: Impact of COVID-19 on Liquid Biopsy Testing Industry
  • Figure 5.13: Implication of COVID-19 on Liquid Biopsy Testing Landscape
  • Figure 5.14: Key Liquid Biopsy Testing Players
  • Figure 5.15: Challenges Faced by Liquid Biopsy Key Players due to COVID-19
  • Figure 5.16: Steps to Mitigate the Impact on COVID-19 on Liquid Biopsy Testing Industry
  • Figure 6.1: Market Dynamics of Global Liquid Biopsy Market
  • Figure 6.2: Cancer Prevalence Trends**, (2013-2017)
  • Figure 6.3: Synergistic Activities, 2018-2019
  • Figure 6.4: SBIR and STTR Grants and Contract Funding 2008-2018
  • Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018
  • Figure 6.6: Case Scenario: NSCLC Liquid Biopsy Coverage Status of Payors
  • Figure 7.1: Share of Key Developments and Strategies, January 2017-January 2019
  • Figure 7.2: Synergistic Activities Share (by Company), January 2017-December 2019
  • Figure 7.3: Accreditations Share (by Company), January 2017-December 2019
  • Figure 7.4: Product and Service Launches Share (by Company), January 2017- December 2019
  • Figure 7.5: Mergers and Acquisitions (by Company), January 2017-December 2019
  • Figure 7.6: Regulatory Approvals (by Company), January 2017-December 2019
  • Figure 7.7: Global Liquid Biopsy Market Share Analysis 2018 Vs 2019
  • Figure 7.8: Growth Share Matrix for Global Liquid Biopsy Market (by Company), 2019
  • Figure 7.9: Growth Share Matrix for Global Liquid Biopsy Market (by Technology), 2019
  • Figure 7.10: Growth Share Analysis (by Indication), 2019
  • Figure 7.11: Growth Share Analysis (by Biomarker Type), 2019
  • Figure 7.12: Growth Share Analysis (by Clinical Application), 2019
  • Figure 8.1: Global Liquid Biopsy Market (by Product), 2020 vs. 2030
  • Figure 8.2: Global Liquid Biopsy Market (by Test/Service), 2019-2030
  • Figure 8.3: Global Liquid Biopsy Market (by Kits and Consumables), 2019-2030
  • Figure 8.4: Global Liquid Biopsy Market (by Instruments), 2019-2030
  • Figure 9.1: Global Liquid Biopsy Market (by Technology), 2020 vs. 2030
  • Figure 9.2: Global Liquid Biopsy Market (by Next Generation Sequencing), 2019-2030
  • Figure 9.3: Global Liquid Biopsy Market (by Polymerase Chain Reaction), 2019-2030
  • Figure 9.4: Global Liquid Biopsy Market (by Digital PCR Technology), 2019-2030
  • Figure 9.5: Global Liquid Biopsy Market (by Multiplex PCR Technology), 2019-2030
  • Figure 9.6: Global Liquid Biopsy Market (by Real-Time PCR Technology), 2019-2030
  • Figure 9.7: Global Liquid Biopsy Market (by Other PCR Technologies), 2019-2030
  • Figure 9.8: Global Liquid Biopsy Market (by FISH), 2019-2030
  • Figure 9.9: Global Liquid Biopsy Market (by Other Technologies), 2019-2030
  • Figure 10.1: Global Liquid Biopsy Market (by Workflow), 2020 Vs. 2030
  • Figure 10.2: Global Liquid Biopsy Market (by Sample Preparation Segment), 2019-2030
  • Figure 10.3: Global Liquid Biopsy Market (by Library Preparation Segment), 2019-2030
  • Figure 10.4: Global Liquid Biopsy Market (by Sequencing Segment), 2019-2030
  • Figure 10.5: Global Liquid Biopsy Market (by Data Analysis and Management Segment), 2019-2030
  • Figure 11.1: Global Liquid Biopsy Market (by Usage), 2020 vs. 2030
  • Figure 11.2: Global Liquid Biopsy Market (by Clinical Applications), 2019-2030
  • Figure 11.3: Global Liquid Biopsy Market (by Research Applications), 2019-2030
  • Figure 12.1: Global Liquid Biopsy Market (by Type of Sample), 2020 vs. 2030
  • Figure 12.2: Global Liquid Biopsy Market (by Blood Sample), 2019-2030
  • Figure 12.3: Global Liquid Biopsy Market (by Urine), 2019-2030
  • Figure 12.4: Global Liquid Biopsy Market (by Saliva), 2019-2030
  • Figure 12.5: Global Liquid Biopsy Market (by Cerebrospinal Fluid), 2019-2030
  • Figure 13.1: Global Liquid Biopsy Market (by Circulating Biomarkers), 2020 vs. 2030
  • Figure 13.2: Global Liquid Biopsy Market (by Circulating Tumor Cells), 2019-2030
  • Figure 13.3: Global Liquid Biopsy Market (by Cell-Free DNA), 2019-2030
  • Figure 13.4: Global Liquid Biopsy Market (by Circulating Cell-Free RNA), 2019-2030
  • Figure 13.5: Global Liquid Biopsy Market (by Exosomes and Extracellular Vesicles), 2019-2030
  • Figure 13.6: Global Liquid Biopsy Market (by Other Biomarkers), 2019-2030
  • Figure 14.1: Global Liquid Biopsy Market (by Indication)
  • Figure 14.2: Global Liquid Biopsy Market (by Indication), 2020 vs. 2030
  • Figure 14.3: Global Liquid Biopsy Market (by Lung Cancer), 2019-2030
  • Figure 14.4: Global Liquid Biopsy Market (by Breast Cancer), 2019-2030
  • Figure 14.5: Global Liquid Biopsy Market (by Prostate Cancer), 2019-2030
  • Figure 14.6: Global Liquid Biopsy Market (by Colorectal Cancer), 2019-2030
  • Figure 14.7: Global Liquid Biopsy Market (by Melanoma), 2019-2030
  • Figure 14.8: Global Liquid Biopsy Market (by Other Type of Cancers), 2019-2030
  • Figure 14.9: Global Liquid Biopsy Market (by Non-Oncology Disorders), 2019-2030
  • Figure 15.1: Global Liquid Biopsy Market (by Clinical Application), 2020 vs. 2030
  • Figure 15.2: Global Liquid Biopsy Market (by Treatment Monitoring), 2019-2030
  • Figure 15.3: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2019-2030
  • Figure 15.4: Global Liquid Biopsy Market (by Treatment Selection), 2019-2030
  • Figure 15.5: Global Liquid Biopsy Market (by Diagnosis and Screening), 2019-2030
  • Figure 16.1: Global Liquid Biopsy Market (by Region), 2020 vs. 2030
  • Figure 16.2: Global Liquid Biopsy Market (by North America), 2020-2030
  • Figure 16.3: Market Dynamics of North American Liquid Biopsy Market
  • Figure 16.4: U.S. Liquid Biopsy Market, 2019-2030
  • Figure 16.5: Cancer Prevalence Trends in the U.S (2013-2017)
  • Figure 16.6: U.S Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.7: U.S Liquid Biopsy Market (by Type of Cancer)
  • Figure 16.8: Canada Liquid Biopsy Market, 2019-2030
  • Figure 16.9: Cancer Prevalence Trends in Canada (2013-2017)
  • Figure 16.10: Canada Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.11: Canada Liquid Biopsy Market (by Types of Cancers)
  • Figure 16.12: Global Liquid Biopsy Market (by Europe), 2020 vs. 2030
  • Figure 16.13: Market Dynamics of European Liquid Biopsy Market
  • Figure 16.14: Germany Liquid Biopsy Market, 2019-2030
  • Figure 16.15: Cancer Prevalence Trends in Germany (2013-2017)
  • Figure 16.16: Germany Liquid Biopsy Market (by Oncology Indication), 2019-2030
  • Figure 16.17: Germany Liquid Biopsy Market by Type of Cancers
  • Figure 16.18: France Liquid Biopsy Market, 2019-2030
  • Figure 16.19: Cancer Prevalence Trends in France (2013-2017)
  • Figure 16.20: France Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.21: France Liquid Biopsy Market by Type of Cancers
  • Figure 16.22: U.K. Liquid Biopsy Market, 2019-2030
  • Figure 16.23: Cancer Prevalence Trends in the U.K. (2013-2017)
  • Figure 16.24: The U.K Liquid Biopsy Market, (by Oncology Indications), 2019-2030
  • Figure 16.25: U.K. Liquid Biopsy Market by Type of Cancers
  • Figure 16.26: Italy Liquid Biopsy Market, 2019-2030
  • Figure 16.27: Cancer Prevalence Trends in Italy (2013-2017)
  • Figure 16.28: Italy Liquid Biopsy Market, (by Oncology Indications), 2019-2030
  • Figure 16.29: Italy Liquid Biopsy Market by Type of Cancers
  • Figure 16.30: Spain Liquid Biopsy Market, 2019-2030
  • Figure 16.31: Cancer Prevalence Trends in Spain (2013-2017)
  • Figure 16.32: Spain Liquid Biopsy Market, (by Oncology Indications), 2019-2030
  • Figure 16.33: Spain Liquid Biopsy Market by Type of Cancers
  • Figure 16.34: Rest-of-Europe Liquid Biopsy Market, 2019-2030
  • Figure 16.35: Asia-Pacific Liquid Biopsy Market, 2020 vs. 2030
  • Figure 16.36: Market Dynamics of Asia-Pacific Liquid Biopsy Market
  • Figure 16.37: China Liquid Biopsy Market, 2019-2030
  • Figure 16.38: Cancer Prevalence Trends in China (2013-2017)
  • Figure 16.39: China Liquid Biopsy Market (by Oncology Indication), 2019-2030
  • Figure 16.40: China Liquid Biopsy Market by Types of Cancer
  • Figure 16.41: Japan Liquid Biopsy Market, 2019-2030
  • Figure 16.42: Cancer Prevalence Trends in Japan (2013-2017)
  • Figure 16.43: Japan Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.44: Japan Liquid Biopsy Market by Types of Cancer
  • Figure 16.45 India Liquid Biopsy Market, 2019-2030
  • Figure 16.46: Cancer Prevalence Trends in India (2013-2017)
  • Figure 16.47: India Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.48: India Liquid Biopsy Market by Type of Cancers
  • Figure 16.49: Australia Liquid Biopsy Market, 2019-2030
  • Figure 16.50: Cancer Prevalence Trends in Australia (2013-2017)
  • Figure 16.51: Australia Liquid Biopsy Market, (by Oncology Indications), 2019-2030
  • Figure 16.52: Australia Liquid Biopsy Market by Types of Cancer
  • Figure 16.53: South Korea Liquid Biopsy Market, 2019-2030
  • Figure 16.54: Cancer Prevalence Trends in South Korea (2013-2017)
  • Figure 16.55: South Korea Liquid Biopsy Market, (by Oncology Indications), 2019-2030
  • Figure 16.56: South Korea Liquid Biopsy Market by Types of Cancer
  • Figure 16.57: Singapore Liquid Biopsy Market, 2019-2030
  • Figure 16.58: Cancer Prevalence Trends in Singapore (2013-2017)
  • Figure 16.59: Singapore Liquid Biopsy Market, (by Oncology Indication), 2019-2030
  • Figure 16.60: Singapore Liquid Biopsy Market by Type of Cancers
  • Figure 16.61: Rest-of-Asia-Pacific Liquid Biopsy Market, 2019-2030
  • Figure 16.62: Latin-America and Middle East Liquid Biopsy Market, 2020 vs. 2030
  • Figure 16.63: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market
  • Figure 16.64: Brazil Liquid Biopsy Market, 2019-2030
  • Figure 16.65: Cancer Prevalence Trends in Brazil (2013-2017)
  • Figure 16.66: Brazil Liquid Biopsy Market (by Oncology Indication), 2019-2030
  • Figure 16.67: Brazil Liquid Biopsy Market by Type of Cancers
  • Figure 16.68: Mexico Liquid Biopsy Market, 2019-2030
  • Figure 16.69: Cancer Prevalence Trends in Mexico (2013-2017)
  • Figure 16.70: Mexico Liquid Biopsy Market (by Oncology Indications), 2019-2030
  • Figure 16.71: Mexico Liquid Biopsy Market by Types of Cancer
  • Figure 16.72: Saudi Arabia Liquid Biopsy Market, 2019-2030
  • Figure 16.73: Cancer Prevalence Trends in Saudi Arabia (2013-2017)
  • Figure 16.74: Saudi Arabia Liquid Biopsy Market (by Oncology Indication), 2019-2030
  • Figure 16.75: Saudi Arabia Liquid Biopsy Market by Types of Cancer
  • Figure 16.76: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2019-2030
  • Figure 16.77: Rest-of-the-World Liquid Biopsy Market, 2019-2030
  • Figure 17.1: Total Number of Companies Profiled
  • Figure 17.2: Abcodia Product Portfolio
  • Figure 17.3: SWOT Analysis: Abcodia Ltd.
  • Figure 17.4: Biocept, Inc.: Portfolio
  • Figure 17.5: Biocept Inc.: Overall Financials, 2017-2019
  • Figure 17.6: Biocept, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.7: SWOT Analysis: Biocept Inc
  • Figure 17.8: Bio-Rad Laboratories, Inc.: Portfolio
  • Figure 17.9: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 17.10: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.11: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 17.12: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.13: SWOT Analysis: Bio-Rad Laboratories Inc.
  • Figure 17.14: Cynvenio Biosystems: Portfolio
  • Figure 17.15: SWOT Analysis: Cynvenio Biosystems Inc.
  • Figure 17.16: Chronix Biomedical: Portfolio
  • Figure 17.17: SWOT Analysis: Chronix Biomedical
  • Figure 17.18: Epic Sciences: Portfolio
  • Figure 17.19: SWOT Analysis: Epic Sciences
  • Figure 17.20: F. Hoffmann-La Roche Ltd: Portfolio
  • Figure 17.21: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 17.22: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
  • Figure 17.23: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
  • Figure 17.24: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 17.25: SWOT Analysis: F. Hoffmann-La Roche Ltd.
  • Figure 17.26: Guardant Health: Portfolio
  • Figure 17.27: Guardant Health: Overall Financials, 2017-2019
  • Figure 17.28: Guardant Health: Sales (by Segment), 2017-2019
  • Figure 17.29: Guardant Health: Sales (by Region), 2017-2019
  • Figure 17.30: Guardant Health: R&D Expenditure, 2017-2019
  • Figure 17.31: SWOT Analysis: Guardant Health Inc.
  • Figure 17.32: Illumina Inc. Portfolio
  • Figure 17.33: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 17.34: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.35: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 17.36: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.37: SWOT Analysis: Illumina Inc.
  • Figure 17.38: Menarini Silicon Biosystems: Portfolio
  • Figure 17.39: SWOT Analysis: Menarini Silicon Biosystems
  • Figure 17.40: Neogenomics Laboratories: Portfolio
  • Figure 17.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 17.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.44: SWOT Analysis: Neogenomics Laboratories
  • Figure 17.45: Personal Genome Diagnostics: Portfolio
  • Figure 17.46: SWOT Analysis: Personal Genome Diagnostics
  • Figure 17.47: QIAGEN N.V.: Portfolio
  • Figure 17.48: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 17.49: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 17.50: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 17.51: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 17.52: SWOT Analysis: Qiagen N.V.
  • Figure 17.53: Resolution Biosciences: Portfolio
  • Figure 17.53: SWOT Analysis: Resolution Biosciences
  • Figure 17.54: Thermo Fisher Scientific: Portfolio
  • Figure 17.55: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 17.56: Thermo Fisher Scientific Inc: Sales (by Segment), $Million, 2017-2019
  • Figure 17.57: Thermo Fisher Scientific Inc.: Sales (by Region), 2017-2019
  • Figure 17.58: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 17.59: SWOT Analysis: Thermo Fisher Scientific Inc.
目次
Product Code: BH00530SC

Title:
Global Liquid Biopsy Market:
Focus on Market Segmentation by Product Type, by Indication Type, by Technology, by Biomarker, by Clinical Applications, by Sample Type, by Usage, By Workflow, Geographical and Competitive Landscape - Analysis and Forecast, 2020-2030.

"Global Liquid Biopsy Market to Reach $12.9 Billion by 2030."

Market Report Coverage - Global Liquid Biopsy

Market Segmentation

  • By Technology: Next-Generation Sequencing, Polymerase Chain Reaction and Other Technologies
  • By Workflow: Sample Collection and Preparation, Library Preparation, Sequencing, and Data Analysis and Management
  • By Usage: Research, Clinical
  • By Sample: Blood, Urine, Saliva, and Cerebrospinal Fluid
  • By Circulating Biomarker: Circulating Tumor Cells,Cell-free DNA,Circulating Cell-Free RNA,Exosomes and Extracellular Vesicles,and Others
  • By Products: Tests/Services, Kits and Consumables, and Instruments
  • By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, and Non-Oncology Disorders
  • By Clinical Application: Treatment Monitoring,Prognosis and Recurrence Monitoring, Treatment Selection, and Diagnosis and Screening
  • By Region: North America, Europe, Asia-Pacific,Latin America and Middle East, and Rest-of-the-World

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, U.K., Italy, Spain, Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, Rest-of-Asia-Pacific
  • Latin America and Middle East - Brazil, Mexico, Saudi Arabia, Rest-of-Latin America and Middle East
  • Rest-of-the-World

Growth Drivers

  • Rising Prevalence of Cancers
  • Increasing Adoption of Inorganic Growth Strategies in the Market
  • Increased NCI funding

Market Challenges

  • False Negatives and Positives
  • Uncertain Reimbursement and Regulatory Scenario
  • Existing Diagnostic Confidence on Standard Tumor Biopsies
  • Expected Implementation of Patient Protection and Affordable Care Act

Market Opportunities

  • Potential Cost Savings
  • Existing Applicability in Non-Availability of Tissue Sections for Traditional Biopsy Approaches
  • Entry of Major Players in the Organ Transplantation Liquid Biopsy Segment

Key Companies Profiled

GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, Cynvenio Biosystems, Chronix Biomedical,Illumina ,and Neogenomics Laboratories, among others.

Key Questions Answered in this Report:

  • What are liquid biopsies? How different settings for liquid biopsieshave evolvedover the centuries?
  • What are the major market drivers, challenges, and opportunities in the global liquid biopsymarket?
  • What was the global liquid biopsy market size in terms of revenue in 2019? How is the market expected to evolve in during the forecast period, 2020-2030? What is the expected market size in 2030?
  • How is each segment of the global liquid biopsy market expected to grow during the forecast period between 2020 to 2030,and what revenue is expected to be generated by each of the segments by the end of 2030?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the global liquid biopsyin different countries?
  • Which service segments among oncology and non-oncology are offered by the key players such asGUARDANT HEALTH, INIVATA, and FOUNDATION MEDICINE?
  • Which liquid biopsy segment led the market in 2019?Which segment is expected to dominate the market by2030, and why?
  • Which application type led the market in 2019?Which segment is expected to dominate the market by2030, and why?
  • Which region dominated the global liquid biopsy market in 2019, and what are the expected trends from each region over the forecast period 2020-2030?

Market Overview

Liquid biopsy is anon-invasive clinical alternative to surgical tissue biopsies. Performing liquid biopsies enables physicians to discover a wider range of information about tumors through the assessment of blood or other fluid-basedsamples from a perspective cancer patient.

Traditionally, the liquid biopsy services were mainly focused on oncology settings, such as treatment decisions, recurrence monitoring, and screening. However, with the advent of new players in the liquid biopsy market, transplant rejection assessment services and infectious disease services based on liquid biopsies areset to become eminent parts of current practices. Several players, such as GUARDANT HEALTH, CareDX, and Chronix Biomedical,currently offer these services in the market. The entry of new players in the market, coupled up with the increased innovation pertaining to cost mitigation and resource output maximization,has been transforming the market currently.

The existing market of liquid biopsy is favored by multiple factors, includingrising prevalence of cancers, increasing adoption of inorganic growth strategies in the market, and increased NCI funding.

Within the research report, the market is segmented on the basis of technology offered by key players (NGS, PCR, FISH, and other technologies), workflow (sample preparation, library preparation, sequencing, and data analysis), usage (RUO and diagnostic), sample (blood and non-blood samples), circulating biomarker (circulating tumor cells, cell-free DNA, circulating RNA, exosomes and extracellular vesicles, and others), product (test/services, kits and consumables, and instruments), oncology indication type (lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and other cancers), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, diagnosis, and screening), and region (North America, Europe, Latin America and Middle East, and Asia-Pacific). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360° coverage of the domain.

Competitive Landscape

Major players, including GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, and Cynvenio Biosystems, among others, led the number of synergistic developments (partnerships and alliances) witnessed in the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed byEurope. The high growth is attributed to the presence of leading industry players in North America, coupled up with therising prevalenceof cancer.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Liquid Biopsy Market: Research Methodology
  • 3.2 Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
    • 3.4.1 Assumptions and Limitations
    • 3.4.2 Data and Prediction Modeling
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Size and Future Growth Potential
  • 4.2 Historical Trends
  • 4.3 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
  • 4.4 Comparative Analysis of Liquid Biopsy Technologies

5 Industry Insights

  • 5.1 Approval Scenario
    • 5.1.1 Approved Liquid Biopsy by Major Players
    • 5.1.2 Launched Liquid Biopsies by Major Players
  • 5.2 Regulatory Framework
    • 5.2.1 Regulatory Framework in the U.S
      • 5.2.1.1 Guidelines Recommendation
      • 5.2.1.2 Regulatory path for liquid biopsy diagnostic approvals
    • 5.2.2 Regulatory Framework in the European Union
    • 5.2.3 Regulation in Other Countries
  • 5.3 Reimbursement Scenario
    • 5.3.1 Case Study for Liquid Biopsy Reimbursement Analysis
  • 5.4 Patent Analysis
    • 5.4.1 Key Players Patent Portfolio
    • 5.4.2 Patent Filing Analysis
    • 5.4.3 Key Players Patent Expiration Analysis
  • 5.5 Financing Scenario
    • 5.5.1 Key Players Stratification (as Per Raised Financing Value)
    • 5.5.2 Key Players Financing Analysis (FY2017-2019)
    • 5.5.3 Investment Heat Map
    • 5.5.4 Investors Heat Map
  • 5.6 Supply Chain Analysis
  • 5.7 Product Mapping Analysis
    • 5.7.1 By Technology
    • 5.7.2 By Sample Type
    • 5.7.3 By Biomarker
    • 5.7.4 By Application
  • 5.8 Physicians Perception
  • 5.9 Investors Perception
  • 5.1 Liquid Biopsy Government Initiatives
  • 5.11 Implication of COVID-19 Pandemic on Liquid Biopsy Market

6 Market Dynamics

  • 6.1 Market Drivers
    • 6.1.1 Rising Cancer Prevalence
    • 6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
    • 6.1.3 Increase in Research Funding from National Cancer Institute
  • 6.2 Market Restraints
    • 6.2.1 False Negatives and Positives
    • 6.2.2 Uncertain Reimbursement and Regulatory Policies
    • 6.2.3 Expected Implementation of Patient Protection and Affordable Care Act in the U.S
    • 6.2.4 Existing Diagnostic Confidence on Traditional Tissue-Based Diagnosis Practices
  • 6.3 Market Opportunities
    • 6.3.1 Potential Cost Savings
    • 6.3.2 Existing Applicability in Non-Availability of Tissue Sections for Traditional Biopsy Approaches

7 Competitive Insights

  • 7.1 Key Strategies and Developments
    • 7.1.1 Synergistic Activities
    • 7.1.2 Regulatory Accreditations
    • 7.1.3 Product and Service Launches
    • 7.1.4 Acquisitions and Mergers
    • 7.1.5 Approvals
  • 7.2 Market Share Analysis, 2019
  • 7.3 Growth Share Analysis
    • 7.3.1 Growth Share Analysis (by Prominent Companies)
    • 7.3.2 Growth Share Analysis (by Technology)
    • 7.3.3 Growth Share Analysis (by Indication)
    • 7.3.4 Growth Share Analysis (by Biomarker Type)
    • 7.3.5 Growth Share Analysis (by Clinical Application)

8 Global Liquid Biopsy Market (by Product)

  • 8.1 Tests/Services
  • 8.2 Kits and Consumables
  • 8.3 Instruments

9 Global Liquid Biopsy Market (by Technology)

  • 9.1 Overview
  • 9.2 Next-Generation Sequencing
  • 9.3 Polymerase Chain Reaction
    • 9.3.1 Digital PCR
    • 9.3.2 Multiplex PCR
    • 9.3.3 Real-Time PCR
    • 9.3.4 Others
    • 9.3.5 Fluorescence In-Situ Hybridization
  • 9.4 Other Technologies

10 Global Liquid Biopsy Market (by Workflow)

  • 10.1 Sample Preparation
  • 10.2 Library Preparation
  • 10.3 Sequencing
  • 10.4 Data Analysis and Management

11 Global Liquid Biopsy Market (by Usage)

  • 11.1 Overview
  • 11.2 Clinical
  • 11.3 Research

12 Global Liquid Biopsy Marker (by Type of Sample)

  • 12.1 Overview
  • 12.2 Blood
  • 12.3 Non-Blood Samples
    • 12.3.1 Urine
    • 12.3.2 Saliva
    • 12.3.3 Cerebrospinal Fluid Samples

13 Global Liquid Biopsy Market (by Circulating Biomarker)

  • 13.1 Circulating Tumor Cells (CTCs)
  • 13.2 Cell-Free DNA (cfDNA)
  • 13.3 Circulating Cell-Free RNAs
  • 13.4 Exosomes and Extracellular Vesicles and Others
  • 13.5 Other Biomarkers

14 Global Liquid Biopsy Market (by Indication)

  • 14.1 Lung Cancer
  • 14.2 Breast Cancer
  • 14.3 Prostate Cancer
  • 14.4 Colorectal Cancer
  • 14.5 Melanoma
  • 14.6 Other Types of Cancer
  • 14.7 Non-Oncology Disorders

15 Global Liquid Biopsy Market (by Clinical Application)

  • 15.1 Treatment Monitoring
  • 15.2 Prognosis and Recurrence Monitoring
  • 15.3 Treatment Selection
  • 15.4 Diagnosis and Screening

16 Global Liquid Biopsy Market (by Region)

  • 16.1 North America
    • 16.1.1 U.S.
      • 16.1.1.1 U.S. Liquid Biopsy Market (by Oncology Indication)
    • 16.1.2 Canada
      • 16.1.2.1 Canada Liquid Biopsy Market (by Oncology Indication)
  • 16.2 Europe
    • 16.2.1 Germany
      • 16.2.1.1 Germany Liquid Biopsy Market (by Oncology Indication)
    • 16.2.2 France
      • 16.2.2.1 France Liquid Biopsy Market (by Oncology Indication)
    • 16.2.3 U.K.
      • 16.2.3.1 U.K. Liquid Biopsy Market (by Oncology Indication)
    • 16.2.4 Italy
      • 16.2.4.1 Italy Liquid Biopsy Market (by Oncology Indication)
    • 16.2.5 Spain
      • 16.2.5.1 Spain Liquid Biopsy Market (by Oncology Indication)
    • 16.2.6 Rest-of-Europe
  • 16.3 Asia-Pacific
    • 16.3.1 China
      • 16.3.1.1 China Liquid Biopsy Market (by Oncology Indication)
    • 16.3.2 Japan
      • 16.3.2.1 Japan Liquid Biopsy Market (by Oncology Indication)
  • 16.4 India
    • 16.4.1 India Liquid Biopsy Market (by Oncology Indication)
    • 16.4.2 Australia
      • 16.4.2.1 Australia Liquid Biopsy Market (by Oncology Indication)
    • 16.4.3 South Korea
      • 16.4.3.1 South Korea Liquid Biopsy Market (by Oncology Indication)
    • 16.4.4 Singapore
      • 16.4.4.1 Singapore Liquid Biopsy Market (by Oncology Indication)
  • 16.5 Rest-of-Asia-Pacific
  • 16.6 Latin America and Middle East
    • 16.6.1 Brazil
      • 16.6.1.1 Brazil Liquid Biopsy Market (by Oncology Indication)
    • 16.6.2 Mexico
      • 16.6.2.1 Mexico Liquid Biopsy Market (by Oncology Indication)
    • 16.6.3 Saudi Arabia
      • 16.6.3.1 Saudi Arabia Liquid Biopsy Market (by Oncology Indication)
    • 16.6.4 Rest-of-Latin America and Middle East
  • 16.7 Rest-of-the-World

17 Company Profiles

  • 17.1 Overview
  • 17.2 Abcodia Ltd.
    • 17.2.1 Company Overview
    • 17.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
    • 17.2.3 SWOT Analysis
  • 17.3 Biocept, Inc.
    • 17.3.1 Company Overview
    • 17.3.2 Role of Biocept, Inc. in Liquid Biopsy Market
    • 17.3.3 Financials
    • 17.3.4 Key Insights About Financial Health of the Company
    • 17.3.5 SWOT Analysis
  • 17.4 Bio-Rad Laboratories, Inc.
    • 17.4.1 Company Overview
    • 17.4.2 Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
    • 17.4.3 Financials
    • 17.4.4 Key Insights About Financial Health of the Company
    • 17.4.5 SWOT Analysis
  • 17.5 Cynvenio Biosystems, Inc.
    • 17.5.1 Company Overview
    • 17.5.2 Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
    • 17.5.3 SWOT Analysis
  • 17.6 Chronix Biomedical
    • 17.6.1 Company Overview
    • 17.6.2 Role of Chronix Biomedical in the Liquid Biopsy Market
    • 17.6.3 SWOT Analysis
  • 17.7 Epic Sciences, Inc.
    • 17.7.1 Company Overview
    • 17.7.2 Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
    • 17.7.3 SWOT Analysis
  • 17.8 F. Hoffmann-La Roche AG
    • 17.8.1 Company Overview
    • 17.8.2 Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
    • 17.8.3 Financials
    • 17.8.4 Key Insights About Financial Health of the Company
    • 17.8.5 SWOT Analysis
  • 17.9 GUARDANT HEALTH, INC
    • 17.9.1 Company Overview
    • 17.9.2 Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
    • 17.9.3 Financials
    • 17.9.4 Key Insights About Financial Health of the Company
    • 17.9.5 SWOT Analysis
  • 17.1 Illumina, Inc.
    • 17.10.1 Company Overview
    • 17.10.2 Role of Illumina, Inc. in the Liquid Biopsy Market
    • 17.10.3 Financials
    • 17.10.4 Key Insights About Financial Health of the Company
    • 17.10.5 SWOT Analysis
  • 17.11 Menarini Silicon Biosystems, Inc.
    • 17.11.1 Company Overview
    • 17.11.2 Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
    • 17.11.3 SWOT Analysis
  • 17.12 NeoGenomics Laboratories, Inc.
    • 17.12.1 Company Overview
    • 17.12.2 Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
    • 17.12.3 Financials
    • 17.12.4 Key Insights About Financial Health of the Company
    • 17.12.5 SWOT Analysis
  • 17.13 Personal Genome Diagnostics, Inc.
    • 17.13.1 Company Overview
    • 17.13.2 Role of Personal Genome Diagnostics in the Liquid Biopsy Market
    • 17.13.3 SWOT Analysis
  • 17.14 Qiagen N.V.
    • 17.14.1 Company Overview
    • 17.14.2 Role of Qiagen N.V. in the Liquid Biopsy Market
    • 17.14.3 Financials
    • 17.14.4 Key Insights about Financial Health of the Company
    • 17.14.5 SWOT Analysis
  • 17.15 Resolution Bioscience, Inc.
    • 17.15.1 Company Overview
    • 17.15.2 Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
    • 17.15.3 SWOT Analysis
  • 17.16 Thermo Fisher Scientific
    • 17.16.1 Company Overview
    • 17.16.2 Role of Thermo Fisher Scientific in the Liquid Biopsy Market
    • 17.16.3 Financials
    • 17.16.4 Key Insights About Financial Health of the Company
    • 17.16.5 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.